The fourth radiopharmaceutical for diagnostics of oncologic pathology was put into production

The Nuclear Medicine Center of Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan summed up the results of the year with positive news - with the launch of the fourth radiopharmaceutical -18F- DOPA.

This drug, produced for the first time in Kazakhstan, has successfully passed all stages of validation activities related to the production of new radiopharmaceutical. This drug is produced for the first time in our country and is aimed at diagnostics of complex neuroendocrine oncological pathology, statistics of which is currently not available in Kazakhstan due to hard-to-diagnose pathology.

4 of the 6 radiopharmaceuticals used at the Hospital’s Nuclear Medicine Center, are manufactured at the Center: 18F- FDG - fludeoxyglucose, 18F-NaF - sodium fluoride, 11C - Met- carbon methionine, 18F-DOPA - dihydroxyphenylalanine, are successfully used for more than 20 types of PET/CT studies, approved diagnostic protocols and rates under the guaranteed volume of free medical care and Compulsory Social Health Insurance.

It should be also noted that 6 more radiopharmaceuticals are planned to be produced by the end of 2026.

The Nuclear Medicine Center, opened in 2022 at Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan, is a unique advanced center that operates according to international requirements of Good Manufacturing Practice (GMP) and gives a great impetus to the development of this industry in the country. But most importantly, the Center provides patients with timely highly qualified highly specialized radioisotope diagnostic services.